These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 4712885)

  • 21. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 23. [Current treatment of Parkinson syndrome with L-dopa].
    Gerstendbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 25. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM; Wiener L
    Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107
    [No Abstract]   [Full Text] [Related]  

  • 26. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 28. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 30. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A; Mars H; Botez MI; Joubert M
    Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopa-decarboxylase inhibitors.
    Lancet; 1973 May; 1(7810):979-80. PubMed ID: 4121597
    [No Abstract]   [Full Text] [Related]  

  • 32. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 33. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C; Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Volante F
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
    Holden EM; Brody JA; Chase TN
    Neurology; 1974 Mar; 24(3):263-5. PubMed ID: 4855953
    [No Abstract]   [Full Text] [Related]  

  • 36. [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].
    Kuzuya F; Wakita T; Kawahara H
    Nihon Naika Gakkai Zasshi; 1972 Sep; 61(9):1131-5. PubMed ID: 4674039
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 38. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 39. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.